Drug Profile
ASP 3662
Alternative Names: ASP-3662Latest Information Update: 01 Aug 2017
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Analgesics; Antidementias
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Diabetic neuropathies
Most Recent Events
- 31 Jul 2017 Discontinued - Phase-II for Alzheimer's disease in USA (PO) (Astellas pipeline, July 2017)
- 31 Jan 2017 Phase-II clinical trials in Alzheimer's disease in USA (PO) (Astellas Pharma pipeline, January 2017)
- 26 Sep 2016 Updated pharmacodynamics data from preclinical studies in Diabetic neuropathies presented at the 16th World Congress of Pain-2016 (WCP-2016)